Alpha Tau Medical’s (DRTS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a report published on Friday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Separately, Piper Sandler reissued an “overweight” rating and issued a $7.00 price target on shares of Alpha Tau Medical in a report on Thursday, August 15th.

Alpha Tau Medical Price Performance

Shares of NASDAQ DRTS opened at $2.32 on Friday. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $3.40. The company has a current ratio of 10.99, a quick ratio of 11.60 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $161.64 million, a price-to-earnings ratio of -5.40 and a beta of 0.77. The firm has a 50-day moving average of $2.28 and a two-hundred day moving average of $2.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Aptus Capital Advisors LLC boosted its holdings in shares of Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares during the period. Financial Guidance Group Inc. boosted its holdings in shares of Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares during the period. Caprock Group LLC acquired a new position in shares of Alpha Tau Medical in the second quarter worth about $59,000. Finally, Levin Capital Strategies L.P. boosted its holdings in shares of Alpha Tau Medical by 2.6% in the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares during the period. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.